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1. Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical
practice, representing a major public health problem. Accumulating evidence suggests
oxidative stress may play an important role in the pathogenesis and perpetuation of AF [1-5].
There are several redox signaling pathways that are possibly related to increased oxidative
stress in the setting of AF, including mitochondrial DNA damage, increased activity of
enzymes such as NADPH oxidase and xanthine oxidase, nitric oxide synthase uncoupling,
activation of pro-arrhythmic transcription factors such as peroxi-some proliferator-activated
receptor, c-fos and NF-κB. In the past few years experimental data and clinical evidence have
tested the concept of antioxidant interventions to prevent AF. Besides statins, ACEIs and/or
ARBs, several other interventions with antioxidant properties, such as Vitamin C and E,
thiazolidinediones, N-acetylcysteine, probucol, nitric oxide donors or precursors, NADPH
oxidase inhibitors, Xanthine oxidase inhibitors have emerged as novel strategies in the
prevention and treatment of AF [6-10]. In this chapter, we aim to summarize recent evidence
regarding antioxidant therapies in the prevention and treatment of atrial fibrillation
2. Vitamin C and E
Recently, antioxidant vitamins C and E have been tested in the prevention of AF, especially
postoperative AF (POAF) [11-14]. These dietary vitamin supplementations have been proven
to protect against the development and progression of AF in experimental models [15, 16].
Vitamin C is a potent water-soluble antioxidant that protects against oxidative stress derived
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by reactive oxygen and nitrogen species. In a canine model of AF, Carnes et al. [15] were the
first to demonstrate that ascorbate attenuates the pacing-induced atrial remodeling and atrial
peroxynitrite production. However, Shiroshita-Takeshita [16] and colleagues did not confirm
the protective effects of Vitamin C and E against AF in their study. Additionaly, tachypacing-
induced atrial effective refractory period shortening and AF promotion were not influenced
by antioxidant vitamins, whereas simvastatin attenuated atrial remodeling and prevented AF.
Recently, Lin et al. [17] investigated whether Vitamin C has direct electrophysiological effects
on isolated rabbit pulmonary vein (PV) preparations. They demonstrated that ascorbic acid
decreases PV spontaneous activity and attenuates the arrhythmogenic effects of hydrogen
peroxide (H2O2). Given that PVs represent major sources of ectopic beats that trigger parox‐
ysmal AF, the potential preventive effects of vitamin C on AF recurrence after PV isolation
should be tested in future clinical trials.
The clinical evidence regarding Vitamin C and E on AF prophylaxis is mainly limited in the
setting of POAF prevention. In a retrospective observational study, Carnes et al. [15] evaluated
the effects of supplemental ascorbate on POAF prevention. A series of 43 consecutive patients
scheduled for coronary artery bypass graft (CABG) surgery were given 2 g ascorbic acid the
night before surgery, followed by 500mg doses twice daily for the 5 days following CABG.
Patients receiving ascorbate had a 16.3% incidence of POAF, in contrast to 34.9% in the control
group (P=0.048). However, multivariate analysis after adjusting for other confounding factors
demonstrated that β-blockers use exhibits the most protective effect (84% risk reduction,
P=0.007) and ascorbate alone was not an independent protector for POAF. In particular, the
two groups were not ideally matched regarding all risk factors for AF, and the incidence of
diabetes, hypertension, and previous history of AF was higher in the control group compared
to the treatment group. Finally, this study may not have enough power to evaluate POAF
incidence.
Eslami et al [18] examined the effects of ascorbic acid as an adjunct to β-blockers in a prospec‐
tive, randomized trial. One hundred patients undergoing CABG surgery were randomized to
the ascorbic acid or to the control group. All patients had been treated with β-blockers for at
least for one week. Patients in the ascorbic acid group received 2 g of ascorbic acid on the night
before the surgery and 1 g twice daily for 5 days following surgery. Patients in the control
group did not receive ascorbic acid. Patients in both groups continued to receive β-blockers
postoperatively. The incidence of POAF was 4% in the Vitamin C group and 26% in the control
group (P=0.002). The authors concluded that ascorbic acid can be prescribed as an adjunctive
therapy to β-blockers for the prophylaxis of POAF. Finally, Papoulidis et al. [19] evaluated the
preventive effects of Vitamin C on POAF incidence in 170 patients undergoing isolated on-
pump CABG. Importantly, all the patients were under β-blockers therapy preoperatively. The
incidence of POAF was 44.7% in the Vitamin C group and 61.2% in the control group (P=0.041).
Notably, patients with Vitmain C had a shorter hospital stay as well as conversion time from
AF into sinus rhythm.
Very recently, in another randomized clinical trial (RCT) [20] which enrolled 152 patients
scheduled for cardiac surgery, the combination of vitamin C (1 g/d) plus vitamin E (400 IU/d)
reduced the risk of POAF in patients aged over 60 years indicating that the efficacy of the
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antioxidant interventions may be improved with aging. In a recent meta-analysis including
five randomized controlled trials with 567 patients, Harling et al. [13] showed that the
prophylactic use of vitamins C and E significantly reduced the incidence of POAF (OR: 0.43,
95% CI: 0.21 to 0.89) as well as the all-cause arrhythmia (OR: 0.54, 95% CI: 0.29 to 0.99) following
cardiac surgery. However, the overall quality of enrolled studies was relatively poor. Un‐
doubtedly, further well-designed studies with enough sample size are warranted in order to
to clarify this issue.
The clinical evidence relating to the potential role of antioxidant vitamins for secondary
prevention of AF is sparse. Korantzopoulos et al. [21] prospectively studied 44 patients
following successful electrical cardioversion of persistent AF. The patients randomized into
Vitamin C group and control group. Within one week, AF recurred in 4.5% of patients in the
vitamin C group and in 36.3% of patients in the control group (P=0.024). Moreover, inflam‐
matory biomarkers decreased after cardioversion in patients receiving vitamin C. Another
recently published study evaluated whether serum Vitamin E level was related to AF recur‐
rence in patients undergoing electrical cardioversion (EC) [22]. One hundred fourty four
consecutive patients who underwent successful EC were prospectively enrolled and followed
for 3 months. It was indicated that low serum Vitamin E level is an independent predictor for
the AF recurrence. Further studies are needed in order to examine the efficacy of antioxidant
vitamin E in AF prevention.
3. Thiazolidinediones
Thiazolidinediones (TZDs) represent a class of insulin-sensiting agents with peroxisome
proliferator-activated receptor-γ (PPAR-γ) activation effects, used to improve insulin resist‐
ance in patients with type 2 diabetes [23, 24]. Troglitazone, the first drug developed and used
clinically, has been withdrawn from the market due to its liver toxicity. Pioglitazone and
rosiglitazone are the only compounds that are available for clinical use now. Apart from their
insulin-sensitizing effects, TZDs have several pleiotropic properties including anti-inflamma‐
tory and antioxidant [25, 26]. It has been demonstrated that PPAR-γ ligands inhibit the
expression of inducible nitric oxide synthase (iNOS) and peroxynitrite production in mesan‐
gial cells and in cerebellar granule cells [27]. Also, TZDs enhance endothelial nitric oxide (NO)
bioavailability, reducing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-
dependent superoxide production, while they induce antioxidant enzymes such as Cu/Zn
superoxide dismutase (Cu/Zn SOD) [28].
Recent experimental evidence indicates that TZDs, especially pioglitazone, prevent atrial
electrical and structural remodeling through their anti-inflammatory and antioxidant proper‐
ties. In a rabbit model of congestive heart failure, pioglitazone attenuated atrial structural
remodeling and inhibited AF promotion, at the same degree as candesartan. Furthermore, the
PPAR-γ activator suppressed transforming growth factor-β (TGF-β), tumor necrosis factor-α
(TNF-α) and extracellular signal-regulated kinase (ERK) expression in atrial tissue. Therefore,
the authors proposed that pioglitazone may inhibit AF by modulating inflammatory, oxidative
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stress, and hypertrophic signaling pathways involved in atrial remodeling [29]. Very recently,
Kume et al. showed that pioglitazone reduced inflammatory atrial fibrosis and vulnerability
to AF in a pressure overload rat model of AF, possibly via the suppression of MCP-1–mediated
inflammatory profibrotic processes [30]. In an in vivo rat model, Xu et al. [31] reported
pioglitazone inhibited age-related atrial structural remodeling and AF susceptibility via its
antioxidant and anti-apoptotic effects. Gene and protein expression levels of antioxidant
molecules such as Mn superoxide dismutase (MnSOD) and heat shock protein (HSP) 70 were
significantly enhanced, whereas NADPH oxidase subunits p22phox and gp91phox were
significantly reduced in aged rats treated with pioglitazone. Therefore, activation of antioxi‐
dant molecules and inhibition of NADPH-derived ROS production may be the mechanisms
underlying the favorable effects of TZDs on aging-related atrial remodeling and AF promotion.
However, experimental data on the effects rosiglitazone on atrial remodeling in the setting of
diabetes is lacking. We have shown that rosiglitazone attenuates atrial structural remodeling
reducing the interatrial activation time and the atrial interstitial fibrosis in alloxan-induced
diabetic rabbits [31].. Also, rosiglitazone treatment increased plasma antioxidant enzyme
superoxide dismutase (SOD) activity and decreased oxidant stress and inflammatory markers
including malondialdehyde (MDA), C-reactive protein (CRP), and TNF-α levels. [32]
We have previously described two patients with diabetes who experienced a remarkable
improvement in their paroxysmal AF episodes following treatment with rosiglitazone [33].
However, two large RCTs, namely RECORD [34] and PROactive [35] which enrolled high-risk
patients with type 2 diabetes failed to demonstrate a significant reduction of AF risk from TZDs
compared with controls. The potential explanations were: firstly, AF was not a predefined
endpoint and reported as an adverse event; secondly, there was a very low AF incidence in
both treatment and control groups (1.5-2%). Also, another case-control study showed that pre-
operative use of TZDs in diabetic patients undergoing cardiac surgery was associated with a
non-statistically significant 20% reduction of POAF [36]. In a prospective cohort study
including 150 diabetic patients undergoing catheter ablation for AF, Gu et al. showed that
previous pioglitazone use was independently associated with a lower recurrence of atrial
tachyarrhythmias during a follow-up period of 23 months [37]. Interestingly, in a recent
observational study Chao et al. [38] investigated the possible association between TZDs use
and development of new-onset AF in 12,605 patients with Type 2 diabetes. During a follow-
up of 5 years, TZDs decreased the risk of new-onset AF by 31% after adjustment for age,
underlying diseases and baseline medications. Although growing evidence suggests TZDs use
prevents the development and recurrence of AF in diabetic patients, the cardiovascular safety
considerations on rosiglitazone recently prompted the European Medicines Agency (EMA) to
suspended this drug from the European market and patients taking rosiglitazone were advised
to discuss alternative options with their physicians [39]. Since November 18, 2011 the FDA
does not allow rosiglitazone to be sold without a prescription from certified doctors. Patients
are required to be informed of the risks associated with the use of rosiglitazone. Therefore, it
is very hard for rosiglitazone to gain a therapeutic indication for AF in the future [40]. Given
the favorable cardiovascular effects of pioglitazone from a recent meta-analysis of 19 RCTs
(including PROactive study) enrolling 16,390 patients [41], further large-scale randomized,
controlled trials with long-term follow-up or a post hoc analysis from previous trials are still
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needed to evaluate the potential role of pioglitazone, as an upstream therapy for AF prevention
in patients with diabetes [42, 43].
4. N-acetylcysteine
N-acetylcysteine (NAC) is a precursor of l-cysteine and glutathione. As a source of sulfhydryl
groups in cells, it may act as a scavenger of free radicals [44]. In clinical practice, NAC is used
as an antioxidant, mucolytic agent widely prescribed in chronic pulmonary disease. Carnes et
al. [45] showed that atrial myocytes from AF patients incubated with NAC lead to a significant
increase in the density of ICa,L. This observation suggests NAC may possibly attenuates atrial
electrophysiological remodeling caused by rapid atrial activation. In a randomized study
including 115 patients undergoing CABG or valve surgery, Ozaydin et al. [46] demonstrated
that NAC markedly reduces the incidence of POAF lasting more than 5 minutes. A previous
meta-analysis [47] evaluated potential beneficial effects of perioperative NAC on the preven‐
tion of complications after cardiothoracic surgery. In the sub-group analysis of six trials which
reported POAF as study endpoints, the use of NAC significantly lowered the risk of developing
POAF by 36%. In a more recent meta-analysis, Gu et al. [48] included 8 randomized trials
incorporating 578 patients, and indicated that NAC significantly reduces the incidence of
POAF by 38% (OR: 0.62, 95% CI: 0.41- 0.93; P =0.021) compared with controls. It is worth
mentioning that only one trial [46] included in this meta-analysis had specified POAF as a
primary endpoint. The remaining seven studies reported POAF as a secondary endpoint.
Therefore, future large-scale randomized studies with an adequate power are urgently in
demand.
5. Probucol
Probucol is a lipid-lowering agent with potent anti-oxidant and anti-inflammatory effects. It
has been used in clinical practice during the past two decades to decrease atherosclerosis and
prevent restenosiss following stent implantation. However, the potential side effects including
decreasing serum high-density lipoprotein cholesterol level and QT prolongation have limited
the probucol's worldwide clinical use [49, 50]. As a potent antioxidant, it may reduce the
production of oxygen free radicals and act as a direct superoxide anion scavenger. In an
isolated perfused rat model, probucol increased the expression of an important myocardial
antioxidant enzyme, namely glutathione peroxidase, and prevented lipid peroxidation
following ischemia reperfusion injury [51]. Moreover, probucol inhibited NADPH oxidase
activity in the aorta from cholesterol-fed rabbits [52]. Our previous studies suggested that
prophylactic treatment with probucol during the periprocedural period in patients undergo‐
ing coronary intervention protects against contrast-induced acute kidney injury [53, 54].
However, experimental studies regarding the possible benefits of probucol on atrial remod‐
eling and AF prevention are lacking. Gong et al. showed that probucol attenuates atrial nerve
sprouting and heterogeneous sympathetic hyperinnervation induced by rapid right atrial
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pacing, and markedly reduces the promotion and maintenance of AF. Also, probucol signifi‐
cantly reduces atrial oxidative stress and increases total antioxidant capacity [55]. A further
study from this group suggested that probucol attenuates structural remodeling and preventes
atrial apoptosis, decreasing the left atrial MDA content in paced dogs [56]. Very recently, we
investigated the effects of probucol on atrial structural and electrical remodeling in alloxan-
induced diabetic rabbits [57]. After treatment for 8 weeks, the diabetic rabbits on probucol
exhibited alleviation of oxidative stress displayed as decreased plasma MDA and increased
plasma SOD levels compared with diabetic controls, while probucol significantly reduced left
atrial interstitial fibrosis and AF inducibility [57]. Therefore, it seems reasonable to speculate
that the antioxidant effects of probucol may favorably affect atrial autonomic and structural
remodeling.
Succinobucol (AGI-1067), a derivative of probucol, is a metabolically stable compound that
has greater intracellular antioxidant efficacy in vitro than probucol without causing a signifi‐
cant prolongation of the QT interval [58]. Surprisingly, the ARISE study [59] showed that use
of succinobucol was associated with increased incidence of new-onset AF in patients with an
acute coronary syndrome. Our previous meta-analysis suggested that increased CRP levels
are associated with greater risk of immediate and short-term AF recurrence following electrical
cardioversion [60, 61]. In this context, although succinobucol have potent antioxidant effects,
its unfavourable influence on CRP levels may be a possible potential explanation for this
undesirable effect [62, 63]. Undoubtedly, further studies are needed to elucidate the precise
role of probucol and succinobucol in atrial remodeling and their clinical impact on AF.
6. Nitric oxide donors or precursors
Nitric oxide is an important endothelium-derived relaxing factor that plays a pivotal role in
the maintenance of vascular tone. NO is synthesized from L-arginine through the effects of
endothelial NO synthase (eNOS) with the critical cofactor tetrahydrobrobiopterin (BH4). BH4
depletion induces NOS uncoupling which shifts the enzymatic activity from NO production
towards superoxide anion (O2 −) production [64]. Endothelial dysfunction (ED) promotes
oxidative stress and inflammation and also impairs NO dependent vaso-relaxation. Endothe‐
lial dysfunction with decreased NO production has been implicated on the development of
atrial fibrillation [65, 66].
It has been indicated that L-Arginine supplementation, as a NO precursor, increases plasma
nitrite levels, decreases MDA release and attenuates ROS mediated myocardial injury [67]. In
a canine tachypacing model of heart failure, Nishijima et al. [68] found increased inducible
NOS in the left atrium which was associated with BH4 depletion, NOS2 uncoupling, and
increased superoxide anion production. These biochemical changes were associated with atrial
electrophysiological changes with increased AF inducibility. BH4 supplementation reduced
atrial oxidative stress and inducibility of atrial fibrillation. Thus, modulation of NOS activity
may be an interesting therapeutic approach to prevent AF [69]. At the clinical level, a pilot
randomized placebo-controlled study examined the potential role of sodium nitroprusside
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(SNP), as a NO donor, in the prevention of POAF [70]. Specifically, 100 consecutive patients
undergoing CABG surgery were randomized to receive SNP (0.5 μg /Kg.min) or placebo
(dextrose 5% in water) during the rewarming period. The occurrence of AF was significantly
lower in the SNP group (P<0.005). Furthermore, the inflammatory biomarker CRP was higher
postoperatively in the control group compared to the SNP group (P<0.05). However, a recent
study didn’t find any association between the use of sodium nitroprusside during cardio‐
thoracic surgery and POAF in a retrospective cohort of 1025 patients undergoing bypass
surgery [71]. Therefore, anti-inflammatory and antioxidant effects of NO may have beneficial
effects on the prevention of POAF. Further randomized controlled studies are urgently needed
to clarify the role of NO and its donor or precursor on the AF prevention.
7. NADPH oxidases inhibitors
NADPH oxidases (NOXs) have been investigated as a key enzymatic source of ROS and seem
to play an important role in the pathogenesis of hypertension, atherosclerosis, and heart failure
[72-74]. NOXs are multi-subunit transmembrane enzymes that utilize NADPH as an electron
donor to reduce oxygen to superoxide anion and hydrogen peroxide. NOX2 and NOX4 are
the most abundant NOX subtypes in cardiomyocytes.
Recent evidence indicates that NOX-derived ROS plays a pivotal role in the development and
maintenance of AF. Dudley et al. [75] showed reduced NO and increased superoxide produc‐
tion production in the left atrial appendage (LAA), which was related to increased NADPH
oxidase activity in an experimental model of atrial tachy-pacing. Of note, the NADPH oxidase
inhibitor apocynin reduced the superoxide production by 91%. In addition, Kim et al. [76]
investigated the sources of superoxide production from the right atrial appendage (RAA) of
patients undergoing cardiac surgery. They indicated that the membrane-bound subunit
gp91phox (NOX2) containing NADPH oxidase was the main source of atrial superoxide
production in human atrial myocytes during sinus rhythm and AF. Also, NADPH-stimulated
superoxide release from RAA homogenates was significantly increased in patients with AF.
In a subsequent study, they measured atrial NADPH oxidase activity in RAA samples from
170 consecutive patients undergoing coronary artery bypass surgery. The multivariate analysis
showed that atrial NADPH oxidase activity was the strongest independent risk factor for the
development of POAF [77]. Remarkably, recent clinical evidence [78] suggests that the
behaviour of NADPH oxidase is related to the type of AF. Cangemi et al. demonstrated that
NOX2 was upregulated in patients with paroxysmal/persistent AF compared with those with
permanent AF and controls [78]. Also, NOX4-derived hydrogen peroxide production is
markedly increased in the LAA tissues of AF patients. Moreover, treatment of HL-1 atrial cells
with angiotensin II, resulted in upregulation of NOX4 and H2O2 production [79]. Bearing in
mind the potent NADPH oxidase inhibitors such as NOX2 inhibitors and apocynin [80] may
be served as potential candidate for the novel preventive agents on AF.
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8. Xanthine oxidase inhibitors
Accumulating evidence suggests that xanthine oxidase (XO) is another important source of
ROS and may relate to atrial remodeling and AF [81]. In a pig model of rapid atrial pacing,
increased XO activity in LAA and reduced superoxide production by 85% following admin‐
istration of oxypurinol (a XO inhibitor) was demonstrated [75]. However, no significant effect
of oxypurinol on superoxide production in human RAA was demonstrated in another study
[76]. A potential explanation for this evident difference is that in the porcine model the
increased XO activity was located in the LAA, whereas RAA specimens were examined in the
human study. Of note, in a similar porcine model, it was demonstrated that after 1 week of
rapid atrial pacing NO expression was decreased in the LAA but not in the RAA, indicating
that the oxidative stress was enhanced only in the left atrium [82].
UA is a metabolic product of purine metabolism produced via the action of XO. Therefore, UA
represents a marker of oxidative stress and inflammation [83, 84]. There is a positive association
between UA levels and AF in different population. In a small observational study, we showed
a stepwise increase of UA levels in patients with paroxysmal AF and permanent AF compared
to controls [85]. It was also demonstrated that high serum UA levels were independent
predictor for AF presence in hypertensive patients [86] and AF recurrence following catheter
ablation [87]. In the ARIC study, a large prospective cohort study, elevated serum UA was
associated with a greater risk of AF development during the follow-up period [88].
No clinical trial to date has examined the effect of allopurinol administration on AF. Only one
observational study reported that patients receiving UA lowering agents had decreased AF
prevalence [89]. In a very recent experimental study using a dog model of atrial tachypacing,
allopurinol suppressed AF promotion by preventing both electrical and structural remodeling,
while it also reduced endothelial NOS protein expression without affecting the left ventricular
ejection fraction or LA diameter [90]. Finally, there are no data on the cardiovascular effects of
the newly released non-purine XO inhibitor febuxostat.
9. Conclusion
A substantial body of evidence indicates that oxidative stress plays a critical role in the
pathophysiology of atrial remodeling. However, the molecular pathways of this pathologic
process are complex and depend on different underlying substrates and concomitant diseases.
Antioxidant therapy seems to be a promising intervention strategy in the prevention of AF
development and perpetuation, at least in the case of POAF. It should be acknowledged that
antioxidant substances may be ineffective in many instances since they act at an advanced
stage of the oxidative damage cascade. On the other hand, interventions that target early steps
of ROS formation seem to be a more promising strategy.
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